Search by Drug Name or NDC
NDC 00069-0342-01 Zirabev 400 mg/16mL Details
Zirabev 400 mg/16mL
Zirabev is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Pfizer Laboratories Div Pfizer Inc. The primary component is BEVACIZUMAB.
MedlinePlus Drug Summary
Bevacizumab injection products are used in combination with other chemotherapy medications to treat cancer of the colon (large intestine) or rectum that has spread to other parts of the body; in combination with other chemotherapy medications to treat certain types of lung cancer that has spread to nearby tissues or other parts of the body, that cannot be removed by surgery, or have returned after treatment with other chemotherapy medications; to treat glioblastoma (a certain type of cancerous brain tumor) that has not improved or has come back after treatment with other medications; in combination with interferon alfa to treat renal cell cancer (RCC, a type of cancer that begins in the kidney) that has spread to other parts of the body; in combination with other chemotherapy medications to treat cervical cancer (cancer that begins in the opening of the uterus [womb]) that has not improved or has come back after treatment with other medications or has spread to other parts of the body; in combination with other chemotherapy medications to treat certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer that has not improved or has come back after treatment with other medications; and Bevacizumab injection (Avastin) is used in combination with atezolizumab to treat hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery in people who have not previously not received chemotherapy. Bevacizumab injection products are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors.
Related Packages: 00069-0342-01Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Bevacizumab Injection
Product Information
| NDC | 00069-0342 |
|---|---|
| Product ID | 0069-0342_ea88c0e2-d853-4382-89da-6661dae624a0 |
| Associated GPIs | 21335020302030 |
| GCN Sequence Number | 079961 |
| GCN Sequence Number Description | bevacizumab-bvzr VIAL 25 MG/ML INTRAVEN |
| HIC3 | V1X |
| HIC3 Description | ANTINEOPLAST HUM VEGF INHIBITOR RECOMB MC ANTIBODY |
| GCN | 46611 |
| HICL Sequence Number | 045849 |
| HICL Sequence Number Description | BEVACIZUMAB-BVZR |
| Brand/Generic | Brand |
| Proprietary Name | Zirabev |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | bevacizumab-bvzr |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 400 |
| Active Ingredient Units | mg/16mL |
| Substance Name | BEVACIZUMAB |
| Labeler Name | Pfizer Laboratories Div Pfizer Inc |
| Pharmaceutical Class | Vascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761099 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00069-0342-01 (00069034201)
| NDC Package Code | 0069-0342-01 |
|---|---|
| Billing NDC | 00069034201 |
| Package | 1 VIAL, SINGLE-USE in 1 CARTON (0069-0342-01) / 16 mL in 1 VIAL, SINGLE-USE |
| Marketing Start Date | 2020-01-13 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |